Invivyd, Inc. (IVVD)

Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval

Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody

Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

These beaten-down stocks could bounce back in January, if history is any guide

3 Small-Cap Biotechs With Binary Catalysts on the Calendar

Invivyd to Participate in Upcoming September Investor Conferences

BlackRock Inc. Takes $14.08 Million Position in Invivyd, Inc. $IVVD

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)